The North America Adenosine Triphosphate (ATP) swab test market is expected to reach US$ 132.91 million by 2027 from US$ 69.83 million in 2019. The market is estimated to grow at a CAGR of 8.4% from 2020 to 2027. The growth of the market is attributed to the key driving factors such as rising prevalence of healthcare associated infections (HAI) and increasing emphasis on food safety. However, the limitations of ATP swab tests hinder the market growth.
The ATP Swab test is a fast calculation by identification of adenosine triphosphate or ATP of aggressively developing microorganisms.ATP is a molecule in and near living cells that explicitly tests the organisms’ biological production and well-being.
Healthcare-associated infectious (HAI) are caused while receiving treatments or therapies in healthcare facilities.These infections are related to surgical procedures and medical instruments used during operations.
The rising prevalence of HAIs is one of the prominent factors driving the demand for ATP swab tests.For instance, according to a study published by the Centers for Disease Control and Prevention (CDC) in 2019, an estimated 1 in 31 hospital patients has some healthcare-associated infection (HAI) across the globe.
Such a substantial prevalence of healthcare-associated disorders propels the adoption of the ATP swab test. Also, the utilization of adenosine triphosphate is a major indicator of cleanliness and sterilization in food & beverages. Hence, the rising incidence of foodborne diseases and food contamination is prominently expected to drive the growth of the North America Adenosine Triphosphate (ATP) swab test market during the forecast period.
The COVID-19 outbreak pandemic is adversely affecting countries in North America.In the US, all sanitization processes at hospitals, medical establishments, and high touch point surfaces in public places utilize Adenosine Triphosphate (ATP) Swab Test to confirm the surface is free from microorganisms, which boosts the growth of the North America Adenosine Triphosphate (ATP) swab test market.
However, the growing number of COVID-19 confirmed cases has resulted in disruption in the supply chain due to a long period of lockdown, which hampers the market growth.
The North America Adenosine Triphosphate (ATP) Swab Test market, based on type, is segmented into free ATP test and microbial ATP test. In 2019, the microbial ATP test segment held a larger market share, and the market for the same segment is expected to grow at a faster rate during the coming years.
The North America Adenosine Triphosphate (ATP) Swab Test market, based on the application, is segmented into pharmaceutical & biotechnology company, food & beverage, hospitals & diagnostics laboratories, and academic & research institutions.In 2019, the pharmaceutical & biotechnology company segment held the largest share of the market.
Moreover, the market for the same segment is expected to grow at the fastest rate during the coming years.
A few of the primary and secondary sources referred to while preparing the report on the North America Adenosine Triphosphate (ATP) swab test market are the American Society of Testing and Material (ASTM), Centers for Disease Control and Prevention (CDC), and World Health organization (WHO).
Our reports have been used by over 10K customers, including:
The global radiotherapy market is valued at USD 6.3 billion in 2022 and is expected to reach USD 8.1 billion by 2027, at a CAGR of 5.1% during the forecast period. Technological advancements in radiotherapy and the rising incidence of cancer are the major factors driving the growth of this market. Additionally, growing awareness of the benefits...
241 pages •
By The Business Research Company
• Jul 2022
Microbiome Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global microbiome market as it emerges from the COVID-19 shutdown. Description: Where is the largest and fastest growing market for microbiome?...
The enzyme replacement therapy market is expected to grow from US$ 9,673.39 million in 2021 to US$ 15,184.70 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028. The report highlights trends prevailing in the market and factors driving the market growth.The growth of the global enzyme replacement therapy market...
The global sleep apnea oral appliances market is valued at an estimated USD 0.7 billion in 2022 and is projected to reach USD 0.3 billion by 2027, at a CAGR of 15.2% during the forecast period. Market growth is driven by factors such as the rising prevalence of sleep apnea and growing demand for alternative treatment options due to poor compliance...
The idiopathic pulmonary fibrosis market is estimated to be USD 3,669.25 million in 2021 and it is expected to reach USD 5,723.69 million by 2027, registering a CAGR of 7.55% from 2022 to 2027. Severe coronavirus disease 2019 (COVID-19) affects the respiratory system and develops into respiratory failure. Patients with pre-existing...
INTRODUCTION In the past two decades, antibody therapeutics have become a key component of the treatment regimens against a range of diseases, specifically cancer. Representing one of the rapidly growing segments of the pharmaceutical industry, a number of technological advancements have been reported in this sector. In...
MarketsandMarkets expects particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027. Market growth is driven by factors such as the various advantages offered by the growing global prevalence of cancer, particle therapy advantages over photon therapy, increasing...
INTRODUCTION RNAi therapeutics have garnered significant attention post the 2006 Nobel Prize that was awarded to Andrew Fire and Craig Mello for the discovery of RNA interference (RNAi). Subsequently, upon the approval of the first RNAi therapeutic, ONPATTRO®, in 2018, the field has witnessed a further surge in activity....
The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to grow at a CAGR of 47.1% from 2021 to 2028. Major factors driving the non-alcoholic steatohepatitis (NASH) market growth include the rising prevalence of NASH and increasing initiatives...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.